This move is anticipated to be the largest shift in federal drug policy in decades. Reclassifying marijuana to Schedule III is expected to facilitate easier research, addressing a long-standing desire among scientists and public health officials. The reclassification is set to have wide-ranging effects and is seen as a historic shift in federal drug policy, with potential implications for medical use,